News >

Study Offers Solution for HER2 Resistance in Breast Cancer

Laura Panjwani
Published: Tuesday, May 19, 2015

Dr Ruth Lupu, PhD,

         Ruth Lupu, PhD

By targeting the HER2 protein’s ability to transform cells, therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) have significantly extended the survival of women with HER2-positive breast cancer. However, major treatment challenges still remain for this breast cancer subtype, according to Ruth Lupu, PhD, professor of Laboratory Medicine and Pathology at Mayo Clinic.

Menendez JA, Schroeder B, Peirce SK, et al. Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling [published online April 17, 2015].  J Natl Cancer Inst. doi: 10.1093/JNCI/djv090.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication